302440 — SK Bioscience Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapFalling Star

Annual income statement for SK Bioscience Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	183,938	225,611	929,001	456,726	369,506
Cost of Revenue
Gross Profit	77,860	95,342	570,283	239,611	142,243
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	161,141	187,900	454,781	341,712	382,647
Operating Profit	22,797	37,710	474,220	115,014	-13,141
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	18,485	37,293	471,128	141,733	7,327
Provision for Income Taxes
Net Income After Taxes	14,677	32,890	355,139	122,452	22,318
Net Income Before Extraordinary Items
Net Income	14,677	32,890	355,139	122,452	22,318
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	14,677	32,890	355,139	122,452	22,318
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	243	530	4,810	1,595	300
Dividends per Share